Probi

Probi has over three decades of clinical research supporting its probiotic strains. Its lead strain, Lactiplantibacillus plantarum LP299V®, has been studied in more than seventy clinical trials with over three hundred peer-reviewed publications. The company’s products are clinically documented for efficacy in digestive, immune, metabolic, bone, women’s and mental health. Recent launches include new synbiotic concepts and expanded offerings targeting metabolic and mental well-being.

In recent years the company has streamlined its portfolio to focus on nine key areas of human wellness.

In May–November of the most recent year it entered new partnerships for product expansion in China and the Nordics.

As of November last year it was acquired by Symrise AG but continues operations as an active subsidiary.

Its products have won industry awards such as NutraIngredients Award for Innovation in Women’s Health.

The pipeline consists primarily of commercialized probiotic solutions rather than traditional drug development programs.

[No ongoing pharmaceutical clinical trials; all major products are commercially available.]

[Proprietary strains/formulations are supported by robust clinical documentation.]